4 biologic agents on hot market competition

Published: 2011-07-12 06:59:00

Updated: 2011-07-12 06:59:00

The domestic biological drugs market so far enjoyed by three companies - Abbott/Eisai's Humira, Johnson & Johnson’s Remicade (infliximab), Wyeth’s Enbrel (etarnercept) - may be encountered with a fierce competition when Bristol-Myers Squibb's Orencia (abatacept) jumps in.

Orencia, the second-line drug in clinical settings here, is the first biologic discovered and developed in Bristol-Myers ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.